Patents by Inventor Anthony B. Schryvers

Anthony B. Schryvers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11872275
    Abstract: Novel methods for exporting target proteins from the cytosol to the extracellular surface of bacterial cells are provided. The methods are useful in that they permit the preparation of vaccines for the prevention of bacterial infectious diseases.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: January 16, 2024
    Assignee: ENGINEERED ANTIGENS INC.
    Inventors: Trevor F. Moraes, Christine Chieh-Lin Lai, Yogesh Hooda, Andrew Judd, Anthony B. Schryvers, Scott D. Gray-Owen
  • Publication number: 20210379176
    Abstract: Novel methods for exporting target proteins from the cytosol to the extracellular surface of bacterial cells are provided. The methods are useful in that they permit the preparation of vaccines for the prevention of bacterial infectious diseases.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 9, 2021
    Inventors: Trevor F. Moraes, Christine Chieh-Lin Lai, Yogesh Hooda, Andrew Judd, Anthony B. Schryvers, Scott D. Gray-Owen
  • Patent number: 11123418
    Abstract: The present disclosure relates to methods for exporting target proteins (e.g., surface lipoproteins) from the cytosol to the extracellular surface of bacterial cells using surface lipoprotein assembly modulator (SLAM) polypeptides. The use of SLAM polypeptides in a method of preparing vaccines useful in the prevention of bacterial infectious diseases is also taught.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 21, 2021
    Assignee: Engineered Antigens Inc.
    Inventors: Trevor F. Moraes, Christine Chieh-Lin Lai, Yogesh Hooda, Andrew Judd, Anthony B. Schryvers, Scott D. Gray-Owen
  • Publication number: 20190117756
    Abstract: The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.
    Type: Application
    Filed: October 25, 2018
    Publication date: April 25, 2019
    Inventors: Anthony B. Schryvers, Trevor F. Moraes, Scott Gray-Owen
  • Publication number: 20190111122
    Abstract: The present disclosure relates to methods for exporting target proteins (e.g., surface lipoproteins) from the cytosol to the extracellular surface of bacterial cells using surface lipoprotein assembly modulator (SLAM) polypeptides. The use of SLAM polypeptides in a method of preparing vaccines useful in the prevention of bacterial infectious diseases is also taught.
    Type: Application
    Filed: February 10, 2017
    Publication date: April 18, 2019
    Inventors: Trevor F. Moraes, Christine Chieh-Lin Lai, Yogesh Hooda, Andrew Judd, Anthony B. Schryvers, Scott D. Gray-Owen
  • Patent number: 10149900
    Abstract: The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: December 11, 2018
    Assignee: Engineered Antigens Inc.
    Inventors: Anthony B. Schryvers, Trevor F. Moraes, Scott Gray-Owen
  • Publication number: 20160303217
    Abstract: The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.
    Type: Application
    Filed: December 1, 2014
    Publication date: October 20, 2016
    Inventors: Anthony B. SCHRYVERS, Trevor F. MORAES, Scott GRAY-OWEN
  • Patent number: 7241449
    Abstract: Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins of M. catarrhalis strains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: July 10, 2007
    Assignee: Aventis Pasteur Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Patent number: 7118749
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: October 10, 2006
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Patent number: 6887686
    Abstract: Cloning and expression of genes encoding H. somnus transferrin-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections, as well as in diagnostic methods for determining the presence of H. somnus infections.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: May 3, 2005
    Assignee: University of Saskatchewan
    Inventors: Andrew A. Potter, Clement Rioux, Anthony B. Schryvers
  • Patent number: 6761914
    Abstract: The present invention provides novel adjuvants which comprise oil bodies. The invention also provides vaccine formulations comprising oil bodies and an antigen and methods for preparing the vaccines and the use of the vaccines to elicit an immune response.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: July 13, 2004
    Assignee: SemBioSys Genetics Inc.
    Inventors: Harm M. Deckers, Gijs van Rooijen, Joseph Boothe, Janis Goll, Maurice M. Moloney, Anthony B. Schryvers, Joenel Alcantara, Wendy A. Hutchins
  • Publication number: 20040081654
    Abstract: The present invention relates to the use of oil bodies as a vaccine adjuvant and delivery system for administration of vaccines by parenteral, mucosal (oral, nasal, pulmonary) and transdermal routes. In addition, the present invention relates to methods of eliciting an immune response in an animal by administering oil body-antigen complexes to said mammal. Finally, the present invention relates to methods of preparing oil body-antigen complexes.
    Type: Application
    Filed: September 15, 2003
    Publication date: April 29, 2004
    Inventors: Anthony B Schryvers, Wendy A Hutchins, Maurice M Moloney, Joenel Alcantra
  • Publication number: 20030088086
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Application
    Filed: January 14, 2002
    Publication date: May 8, 2003
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Publication number: 20030007981
    Abstract: Cloning and expression of genes encoding H. somnus transferrin-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections, as well as in diagnostic methods for determining the presence of H. somnus infections.
    Type: Application
    Filed: March 13, 2002
    Publication date: January 9, 2003
    Applicant: University of Saskatchewan
    Inventors: Andrew A. Potter, Clement Rioux, Anthony B. Schryvers
  • Patent number: 6440701
    Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: August 27, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Patent number: 6437096
    Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
    Type: Grant
    Filed: January 3, 1997
    Date of Patent: August 20, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Publication number: 20020071846
    Abstract: The present invention provides novel adjuvants which comprise oil bodies. The invention also provides vaccine formulations comprising oil bodies and an antigen and methods for preparing the vaccines and the use of the vaccines to elicit an immune response.
    Type: Application
    Filed: June 15, 2001
    Publication date: June 13, 2002
    Inventors: Harm M. Deckers, Gijs Van Rooijen, Joseph Boothe, Janis Goll, Maurice M. Moloney, Anthony B. Schryvers, Joenel Alcantara, Wendy A. Hutchins
  • Patent number: 6391316
    Abstract: Cloning and expression of genes encoding H. somnus transferrin-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections, as well as in diagnostic methods for determining the presence of H. somnus infections.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: May 21, 2002
    Assignee: University of Saskatchewan
    Inventors: Andrew A. Potter, Clement Rioux, Anthony B. Schryvers
  • Patent number: 6361779
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: March 26, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Patent number: 6358727
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbpl or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: March 19, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein